Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma

Xie, Hongjun; Shi, Muqi; Liu, Yifei; Cheng, Changhong; Song, Lining; Ding, Zihan; Jin, Hui-pei; Cui, Xiaohong; Wang, Yan; Yao, Dengfu; Wang, Peng; Yao, Min; Zhang, Haijian

doi:10.3389/fimmu.2022.914977

Cited by 14 publications

(8 citation statements)

References 68 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and our results suggested a higher infiltration rate of resting myeloid DCs in the high-risk group, which may contribute to a poorer immune response. The data from the ESTIMATE method showed that the high-risk group had a higher immune score, which could represent the higher levels of immune cell infiltration in the TME and was consistent with previous studies (58,59). However, our study showed that high risk patients had poor immunotherapy response and high immune cell infiltration levels did not mean a better immunotherapy response.…”

Section: Discussionsupporting

confidence: 91%

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Zhu

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and CD4+ T lymphocytes can inhibit hepatocarcinogenesis and mediate tumor regression. However, few studies have focused on the prognostic power of CD4+ Tconv-related lncRNAs in HCC patients.MethodWe obtained data from TCGA and GEO databases and identified CD4+Tconv-related lncRNAs in HCC. The risk score was constructed using lasso regression and the model was validated using two validation cohorts. The RS was also assessed in different clinical subgroups, and a nomogram was established to further predict the patients’ outcomes. Furthermore, we estimated the immune cell infiltration and cancer-associated fibroblasts (CAFs) through TIMER databases and assessed the role of RS in immune checkpoint inhibitors response.ResultsWe constructed a CD4+ Tconv-related lncRNAs risk score, including six lncRNAs (AC012073.1, AL031985.3, LINC01060, MKLN1-AS, MSC-AS1, and TMCC1-AS1), and the RS had good predictive ability in validation cohorts and most clinical subgroups. The RS and the T stage were included in the nomogram with optimum prediction and the model had comparable OS prediction power compared to the AJCC. Patients in the high-risk group had a poor immune response phenotype, with high infiltrations of macrophages, CAFs, and low infiltrations of NK cells. Immunotherapy and chemotherapy response analysis indicated that low-risk group patients had good reactions to immune checkpoint inhibitors.ConclusionWe constructed and validated a novel CD4+ Tconv-related lncRNAs RS, with the potential predictive value of HCC patients’ survival and immunotherapy response.

show abstract

Section: Discussionsupporting

confidence: 91%

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Zhu

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…For example, L et al constructed an m6A-associated lncRNA signature to predict prognosis and immunotherapy of HCC 27 . The results showed that the predictive accuracy of this model was higher than that of other clinical signatures; the value of the model built by Xie et al using lncRNAs based on m6A and ferroptosis co-associated lncRNAs was superior to the former 28 . Thus, we believe that a prognostic model that combines multiple biomarkers is more appropriate.…”

Section: Introductionmentioning

confidence: 81%

Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in thymoma

Hao

Sun

2023

Preprint

View full text Add to dashboard Cite

BACKGROUND: N6-methyladenosine (m6A) methylation and ferroptosis assist long non-coding RNAs (lncRNAs) to promote immune escape in thymoma (THYM). However, the predictive power of m6A and ferroptosis-associated lncRNAs in immune potency remains unknown. METHODS: A total of 120 THYM samples with complete data were obtained from The Cancer Genome Atlas (TCGA) database as the training cohort, and half of them were randomly composed as the validation cohort, and various methods such as regression analysis and enrichment analysis were applied to screen, evaluate, etc. RESULTS: We constructed prognosis-associated mfrlncRNA pairs after screening for lncRNAs associated with m6A regulators and ferroptosis-associated genes. According to this, the mfrlncRNA signature was founded utilizing least absolute shrinkage and selection operator (LASSO) analysis and Cox regression. We found that patients' risk score was an independent risk factor and was much better than clinical stage as an indicator. In addition, patients in the high-risk group had a poorer prognosis with higher B cells naive and Macrophages M0/M1/M2 infiltration, lower Plasma cells and T cells CD4 naive infiltration, higher immune escape potential (higher TIDE score) and higher IC50. Finally, mfrlncRNA signature contributes to risk prediction in THYM patients and prognostic improvement. CONCLUSIONS: The mfrlncRNA signature has great prognostic value and may help to explore the relevant immune mechanisms in depth, with key implications for individualized treatment to improve the prognosis of THYM patients.

show abstract

“…Although several ferroptosis-associated lncRNAs have been analyzed for their correlation with m6A-related genes in terms of immune efficacy 115 , 116 , 117 , few studies have investigated the specific targets or pathways of m6A and ferroptosis in immune therapy. Given that ferroptosis and m6A play critical roles in tumors, further research on m6A-modified ferroptosis in diverse cancers is needed.…”

Section: The Combination Of M6a and Pcd In Cancersmentioning

confidence: 99%

Novel insights into the interplay between m6A modification and programmed cell death in cancer

Chen¹,

Ye²,

Bai³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

N6-methyladenosine (m6A) methylation, the most prevalent and abundant RNA modification in eukaryotes, has recently become a hot research topic. Several studies have indicated that m6A modification is dysregulated during the progression of multiple diseases, especially in cancer development. Programmed cell death (PCD) is an active and orderly method of cell death in the development of organisms, including apoptosis, autophagy, pyroptosis, ferroptosis, and necroptosis. As the study of PCD has become increasingly profound, accumulating evidence has revealed the mutual regulation of m6A modification and PCD, and their interaction can further influence the sensitivity of cancer treatment. In this review, we summarize the recent advances in m6A modification and PCD in terms of their interplay and potential mechanisms, as well as cancer therapeutic resistance. Our study provides promising insights and future directions for the examination and treatment of cancers.

show abstract

Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma

Cited by 14 publications

References 68 publications

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in thymoma

Novel insights into the interplay between m6A modification and programmed cell death in cancer

Contact Info

Product

Resources

About